Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine entities : Vir biotechnology, inc. save search
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
Published: 2023-09-20 (Crawled : 12:00) - globenewswire.com
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -0.3%
H: 0.61%
C: -4.58%
vir-1388 vaccine cell hiv
Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention
Published: 2023-05-02 (Crawled : 13:00) - globenewswire.com
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -0.6%
H: 0.52%
C: -1.56%
vaccine cell grant hiv platform
Preclinical Data Highlight the Significant Antigenic Shift of the Omicron SARS-CoV-2 Variant and its Effect on the Neutralizing Activity of Monoclonal Antibodies, Convalescent Antibodies and Vaccine-Elicited Antibodies
Published: 2021-12-14 (Crawled : 23:00) - globenewswire.com
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: 3.02%
H: 6.19%
C: 5.15%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 6.71%
H: 10.12%
C: 5.09%
monoclonal antibodies preclinical sars-cov-2 vaccine antibody pre-clinical
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
Published: 2021-12-07 (Crawled : 14:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 5.22%
H: 0.0%
C: -1.25%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -6.42%
H: 8.6%
C: 8.45%
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 6.57%
H: 14.77%
C: 11.21%
RDHL | $0.415 -2.99% -3.08% 190K
|
Health Technology
|
| O: 0.37%
H: 10.37%
C: 9.63%
covid vaccine
Global $9.5 Billion Influenza Vaccines Market to 2027
Published: 2021-07-27 (Crawled : 11:00) - prnewswire.com
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.41%
H: 1.0%
C: 0.87%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -0.68%
H: 2.23%
C: -0.76%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.54%
H: 0.65%
C: 0.49%
vaccine influenza
Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
Published: 2021-06-23 (Crawled : 11:00) - vbivaccines.com
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -0.34%
H: 2.23%
C: -0.86%
VBIV | $0.5893 -3.16% -3.26% 130K
|
Health Technology
|
| O: 1.03%
H: 1.53%
C: -0.76%
hepatitis phase 1 positive vbi-2601 vaccine liver phase 1b phase 2b chronic hepatitis b
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
Published: 2021-04-21 (Crawled : 12:00) - vbivaccines.com
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -1.09%
H: 0.38%
C: 0.04%
VBIV | $0.5893 -3.16% -3.26% 130K
|
Health Technology
|
| O: 0.0%
H: 7.66%
C: 7.66%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.67%
H: 1.12%
C: 0.43%
treatment phase 2 hepatitis vbi-2601 biotech vaccine technology iot brii-835 trial
Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform– Culmination of a decade-long collaboration with Oregon Health & Science University and the Bill & Melinda Gates Foundation –
Published: 2021-01-06 (Crawled : 18:00) - biospace.com/
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -0.57%
H: 4.54%
C: 1.26%
collaboration biotech vaccine trial phase 3 phase 1 phase 2 decades
Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform
Published: 2021-01-06 (Crawled : 13:03) - globenewswire.com
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -0.57%
H: 4.54%
C: 1.26%
biotech vaccine trial phase 3 phase 1 phase 2 platform
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.